J B Chemicals & Pharmaceuticals has registered growth of 72.3 per cent in its earnings before depreciation, interest, taxation and adjustments during the third quarter ended December 2013 to Rs.67.20 crore from Rs.39.01 crore in the corresponding period of last year. However, it incurred a net loss of Rs.6.47 crore on account of provision of Rs.64.50 crore following commercial settlement of disputes with Cilag GmbH International regarding its Russia-CIS OTC business.

Its net sales moved up by 17.3 per cent to Rs.234.22 crore from Rs.199.76 crore due to favourable product mix. The domestic formulations business improved by 20.3 per cent to Rs.85.77 crore The concentration on growth of focus products and better field efficiency has helped achieve better performance in the domestic market. Its formulations exports improved by 12.3 per cent to Rs.119.21 crore. Out of this, exports to Rest of the World markets registered strong growth of 28.7 per cent to Rs.100.71 crore. Its sales in Russia-CIS region amounted to Rs.18.49 crore. Sales of APIs increased by 59.2 per cent to Rs.26.41 crore.

For the nine months ended December 2013, J B Chemicals' net sales increased by 19.1 per cent to Rs.710.83 crore from Rs.596.73 crore in the similar period of last year and its EBDITA improved by 41.5 per cent to Rs.166.29 crore from Rs.117.53 crore. However, after provision of Rs.67.20 crore for above mentioned settlement of disputes, its net profit declined by 27.9 per cent to Rs.46.99 crore from Rs.65.18 crore. EPS for the nine months worked out to Rs.5.55 as against Rs.7.70 in the last period. Its domestic formulations business increased by 16.3 per cent and APIs sales went up by 70.1 per cent. Its sales in Russia-CIS region reached at Rs.69.21 crore.